Endothelin-1 is Increased in the Plasma of Patients Hospitalized with Covid-19
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Virus induced endothelial dysregulation is a well-recognised feature of severe Covid-19 infection. Endothelin-1 (ET-1) is the most highly expressed peptide in endothelial cells and a potent vasoconstrictor, thus representing a potential therapeutic target.
ET-1 plasma levels were measured in a cohort of 194 Covid-19 patients stratified according to the clinical severity of their illness. Hospitalised patients, including those who died and those developing acute myocardial or kidney injury, had significantly elevated ET-1 plasma levels during the acute phase of infection.
The results support the hypothesis that endothelin receptor antagonists may provide clinical benefit for certain Covid-19 patients.
Description
Keywords
Covid-19, Endotheliitis, Endothelin receptor antagonists, Endothelin-1, COVID-19, Endothelial Cells, Endothelin Receptor Antagonists, Endothelin-1, Humans, Receptor, Endothelin A, Receptors, Endothelin, Vasoconstrictor Agents
Journal Title
Journal of Molecular and Cellular Cardiology
Conference Name
Journal ISSN
0022-2828
1095-8584
1095-8584
Volume Title
Publisher
Elsevier
Publisher DOI
Sponsorship
Wellcome Trust (107715/Z/15/Z)
British Heart Foundation (TG/18/4/33770)
MRC (via University of Glasgow) (303684)
National Institute for Health and Care Research (IS-BRC-1215-20014)
British Heart Foundation (TG/18/4/33770)
MRC (via University of Glasgow) (303684)
National Institute for Health and Care Research (IS-BRC-1215-20014)
Supported in full or part by The Jon Moulton Charity Trust, National Institute of Health Research, Cambridge Biomedical Research Centre, BRC-1215-20014 (JC); Wellcome Trust (WT107715/Z/15/Z), Biomedical Resources Grant, University of Cambridge, Cardiovascular Theme RG64226, British Heart Foundation, TG/18/4/33770,